Stock comparison
LeMaitre Vascular
Phibro Animal Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
PAHC
Phibro Animal Health
Market cap
$1.47B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | PAHC | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 41D | LMAT |
| Benjamin Graham | 81A | 74B | LMAT |
| Philip Fisher | 73B | 25F | LMAT |
| Peter Lynch | 59C | 29F | LMAT |
| Joel Greenblatt | 48D | 38D | LMAT |
| Charlie Munger | 60C | 36D | LMAT |
| Terry Smith | 61C | 32F | LMAT |
Side-by-side metrics
| Metric | LMAT | PAHC |
|---|---|---|
| Market cap | $2.32B | $1.47B |
| P/E (TTM) | 37.1x | 15.5x |
| EV/EBIT | 36.6x | 20.0x |
| ROIC (TTM) | 9.43% | 11.17% |
| Gross margin | 72.39% | 32.54% |
| Net margin | 24.35% | 6.35% |
| Revenue CAGR 5y | 12.75% | 11.68% |
| EPS CAGR 5y | 19.04% | -2.92% |
| Debt / Equity | 0.5x | 2.2x |
| Dividend yield | 0.84% | 1.32% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs -2.92%+115%
- Debt / Equity0.5xvs 2.2x+79%
- Net margin24.35%vs 6.35%+74%
- Gross margin72.39%vs 32.54%+55%
PAHC leads on
- P/E (TTM)15.5xvs 37.1x+58%
- EV/EBIT20.0xvs 36.6x+45%
- Dividend yield1.32%vs 0.84%+37%
- ROIC (TTM)11.17%vs 9.43%+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.